DRP1 Binding Assay for Mitochondrial Toxicity Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting and assessing mitochondrial toxicity of drugs are inadequate, leading to drug-induced toxicity issues in clinical trials and post-marketing, necessitating a more effective and earlier detection of potential cytotoxic effects.
Innovation Solution
The method involves detecting specific binding between a compound and the DRP1 protein, particularly at its GTPase domain, using molecular docking and in vitro assays, followed by cell-based cytotoxicity tests to assess cytotoxicity, particularly in cardiomyocytes, to identify potential mitochondrial toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional toxicity assessment methods are used, then extensive animal or human testing can be performed, but the risk of drug-induced mitochondrial toxicity remains high and costly
Solution Approach 1:
The patent performs preliminary toxicity assessment by detecting compound binding to the DRP1 protein at its GTPase domain before conducting extensive animal or human testing. This preliminary action identifies compounds with high probability of mitochondrial toxicity, allowing early elimination of toxic candidates and reducing the need for complex subsequent testing while improving prediction reliability
Solution Approach 2:
The patent introduces DRP1 protein binding detection as an intermediary step between compound screening and final toxicity confirmation. This intermediary assay provides a simplified, high-throughput method to predict mitochondrial toxicity with high accuracy, bridging the gap between simple chemical screening and complex in vivo testing
2Loss of time
If early toxicity detection methods are implemented, then compounds with high cytotoxicity chances can be identified before animal testing, but additional binding detection steps are required
Solution Approach 1:
The patent extracts the critical toxicity-predicting interaction (compound-DRP1 binding at GTPase domain) from the complex in vivo toxicity pathway. By isolating and detecting this specific molecular interaction in vitro, the method achieves early toxicity prediction without requiring time-consuming animal studies, as the binding event serves as a reliable surrogate for mitochondrial toxicity
Solution Approach 2:
The patent replaces complex mechanical in vivo toxicity testing systems with a simplified biochemical binding detection system. The in vitro DRP1 binding assay substitutes for extensive animal or human testing, dramatically reducing assessment time while maintaining predictive accuracy through direct detection of the molecular interaction that precedes toxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for early and accurate prediction of drug toxicity, reducing the risk of drug-induced mitochondrial toxicity by identifying compounds with high chances of cytotoxicity, thereby preventing further testing in animals or humans.
Implementation Method 1
detecting specific binding between the compound and DRP1 protein at its GTPase domain
Implementation Method 2
step (1) of the method comprises simulating binding between the compound and the GTPase domain by molecular docking
Implementation Method 3
contacting the DRP1 protein or the GTPase domain of the DRP1 protein with the compound, for example, in an in vitro assay where the compound and the DRP1 protein or a fragment of the DRP1 protein comprising the GTPase domain or its GTPase domain are placed together under conditions permissible for their interaction
Data Source
AI summary
The present invention provides methods for assessing a compound's potential toxicity.